CoQ10 Early-Stage Parkinson's Disease Trial Nearing Completion
This article was originally published in The Tan Sheet
Executive Summary
A prospective, randomized, double-blind clinical trial examining coenzyme Q10's effectiveness at treating Parkinson's disease will be completed this month, with results slated for release at the end of the year.
You may also be interested in...
High-Dose CoQ10 Research Urged In UCSD Early Parkinson’s Study
Early-stage Parkinson's disease patients given 1,200 mg/day coenzyme Q10 experienced slower disease progression than those receiving 300 mg/d, 600 mg/d or placebo, a recent Phase II study found
High-Dose CoQ10 Research Urged In UCSD Early Parkinson’s Study
Early-stage Parkinson's disease patients given 1,200 mg/day coenzyme Q10 experienced slower disease progression than those receiving 300 mg/d, 600 mg/d or placebo, a recent Phase II study found
High-Dose CoQ10 Research Urged In UCSD Early Parkinson’s Study
Early-stage Parkinson's disease patients given 1,200 mg/day coenzyme Q10 experienced slower disease progression than those receiving 300 mg/d, 600 mg/d or placebo, a recent Phase II study found